Ind-Swift Laboratories Limited (INDSWFTLAB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Ind-Swift Laboratories Limited (INDSWFTLAB) has a cash flow conversion efficiency ratio of -0.015x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs-202.50 Million ≈ $-2.19 Million USD) by net assets (Rs13.07 Billion ≈ $141.39 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Ind-Swift Laboratories Limited net asset quality index to measure how much of total assets are equity-financed.
Ind-Swift Laboratories Limited - Cash Flow Conversion Efficiency Trend (2006–2025)
This chart illustrates how Ind-Swift Laboratories Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Ind-Swift Laboratories Limited (INDSWFTLAB) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Ind-Swift Laboratories Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Ind-Swift Laboratories Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Imexpharm Corp
VN:IMP
|
0.044x |
|
Old Point Financial Corporation
NASDAQ:OPOF
|
0.014x |
|
Community Bancorp. Common Stock
NASDAQ:CMTV
|
0.035x |
|
Ontex Group NV
BR:ONTEX
|
0.072x |
|
Anhui Yuanchen Environmental Protection Science & Technology Co. Ltd.
SHG:688659
|
0.002x |
|
Caswell Inc
TW:6416
|
-0.038x |
|
Awfis Space Solutions Ltd
NSE:AWFIS
|
0.565x |
|
Kimteks Poliuretan Sanayi ve Ticaret AS
IS:KMPUR
|
0.157x |
Annual Cash Flow Conversion Efficiency for Ind-Swift Laboratories Limited (2006–2025)
The table below shows the annual cash flow conversion efficiency of Ind-Swift Laboratories Limited from 2006 to 2025. For the full company profile with market capitalisation and key ratios, see Ind-Swift Laboratories Limited (INDSWFTLAB) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | Rs11.73 Billion ≈ $126.85 Million |
Rs-254.74 Million ≈ $-2.75 Million |
-0.022x | +89.19% |
| 2024-03-31 | Rs8.12 Billion ≈ $87.82 Million |
Rs-1.63 Billion ≈ $-17.64 Million |
-0.201x | -170.38% |
| 2023-03-31 | Rs6.82 Billion ≈ $73.75 Million |
Rs1.95 Billion ≈ $21.05 Million |
0.285x | +14.11% |
| 2022-03-31 | Rs6.01 Billion ≈ $64.98 Million |
Rs1.50 Billion ≈ $16.25 Million |
0.250x | +11.83% |
| 2021-03-31 | Rs6.03 Billion ≈ $65.26 Million |
Rs1.35 Billion ≈ $14.59 Million |
0.224x | +14.40% |
| 2020-03-31 | Rs6.41 Billion ≈ $69.28 Million |
Rs1.25 Billion ≈ $13.54 Million |
0.195x | +278.44% |
| 2019-03-31 | Rs5.88 Billion ≈ $63.57 Million |
Rs-644.00 Million ≈ $-6.96 Million |
-0.110x | -182.93% |
| 2018-03-31 | Rs5.53 Billion ≈ $59.83 Million |
Rs730.90 Million ≈ $7.90 Million |
0.132x | -26.55% |
| 2017-03-31 | Rs5.31 Billion ≈ $57.46 Million |
Rs955.66 Million ≈ $10.34 Million |
0.180x | +17.17% |
| 2016-03-31 | Rs5.17 Billion ≈ $55.96 Million |
Rs794.30 Million ≈ $8.59 Million |
0.154x | -7.25% |
| 2015-03-31 | Rs5.95 Billion ≈ $64.30 Million |
Rs983.98 Million ≈ $10.64 Million |
0.166x | +83.17% |
| 2014-03-31 | Rs7.25 Billion ≈ $78.43 Million |
Rs655.29 Million ≈ $7.09 Million |
0.090x | +265.47% |
| 2013-03-31 | Rs8.53 Billion ≈ $92.30 Million |
Rs-466.03 Million ≈ $-5.04 Million |
-0.055x | -161.11% |
| 2012-03-31 | Rs8.12 Billion ≈ $87.78 Million |
Rs725.24 Million ≈ $7.84 Million |
0.089x | +193.19% |
| 2011-03-31 | Rs5.84 Billion ≈ $63.10 Million |
Rs177.83 Million ≈ $1.92 Million |
0.030x | -69.08% |
| 2010-03-31 | Rs4.48 Billion ≈ $48.48 Million |
Rs441.84 Million ≈ $4.78 Million |
0.099x | -64.25% |
| 2009-03-31 | Rs3.63 Billion ≈ $39.27 Million |
Rs1.00 Billion ≈ $10.83 Million |
0.276x | +61.91% |
| 2008-03-31 | Rs3.33 Billion ≈ $36.06 Million |
Rs567.77 Million ≈ $6.14 Million |
0.170x | +17.18% |
| 2007-03-31 | Rs3.11 Billion ≈ $33.68 Million |
Rs452.62 Million ≈ $4.89 Million |
0.145x | +137.58% |
| 2006-03-31 | Rs1.92 Billion ≈ $20.80 Million |
Rs117.63 Million ≈ $1.27 Million |
0.061x | -- |
About Ind-Swift Laboratories Limited
Ind-Swift Laboratories Limited, together with its subsidiaries, develops, manufactures, and sells active pharmaceutical ingredients (APIs), intermediates, and formulations in India and internationally. The company offers APIs in various therapeutic areas, including macrolide antibiotic, cardiovascular, antihistaminic, antidiabetic, antipsychotic, bone resorption inhibitor, Parkinson's disease, hy… Read more